Acute ischemic stroke
Conditions
Interventions
Gold Standard:
Index test:
Sponsors
Beijing Tiantan Hospital of Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-80 years; 2. Patients' clinical diagnosis is ischemic stroke with neurological deficit such as the impairment of language, motor function and cognition, gaze deficit, visual field defects and/or visual neglect. Ischemic stroke is defined as acute localized neurological deficit which start suddenly, the supposed reason is ischemic of brain without hemorrhage confirmed by CT; 3. Multimodal-MR screening to be started within 8 hrs after stroke onset; 4. The responsible foci has no abnormal on DWI (b=0) but high signal on DWI (b=1000) and low signal on ADC; 5. No obvious sequelae are left behind from the first or past stroke (mRS<=2); 6. Stroke symptoms present for at least 30 min and has not significantly improved before treatment. The symptoms must be distinguished from the symptom of Global Cerebral Ischemia (such as swoon), epilepsia and hemicrania; 7. Patients are willing to give informed consent; 8. Patients are willing and able to comply with the study protocol; 9. Patients without MR contraindications (claustrophobia, cardiac pacemakers, or metal implants).
Exclusion criteria
Exclusion criteria: 1. Presenting obvious neurologic deficits because of past stroke [modified Rankin Scale (mRS) >2]; 2. Coma or severe stroke as assessed clinically (e.g. NIHSS >25); 3. Seizure at onset of stroke; 4. Uncompensated hypertension at study entry or hypertension requiring aggressive treatment to reduce blood pressure to nonhypertensive limits. Uncompensated hypertension is defined as systolic blood pressure >185 mm Hg or diastolic blood pressure >=110 mm Hg on 3 repeated measures at least 10 minutes apart; 5. Evidence of intracranial haemorrhage (ICH), brain tumors, vascular malformation, aneurysm, subarachnoid Hemorrhage (SAH); 6. Known haemorrhagic diathesis within the last 6 months; arterial aneurysm, arterial/venous malformation; neoplasm with increased bleeding risk; Severe liver disease, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis; 7. Patients receiving oral anticoagulants, e.g. warfarin sodium, and coagulant response time (INR) >1.5; 8. Prior stroke within the last 3 months; 9. Patients with any history of prior stroke and concomitant diabetes; 10. Any history of severe central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery); haemorrhagic retinopathy,e.g. in diabetes (vision disturbances may indicate haemorrhagic retinopathy); bacterial endocarditis, pericarditis; acute pancreatitis; documented ulcerative gastrointestinal disease during the last 3 months; pregnancy or lactation; 11. Prolonged traumatic external heart massage, or recent (less than 10 days) obstetrical delivery or recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture); 12. Blood glucose 400 mg/dl.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Initial infarction core;Ischemic penumbra;Type of hemorrhagic transformation;Final infarct volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean transit time;Time to peak;Cerebral blood flow;Cerebral blood volume; | — |
Countries
China
Contacts
Public ContactJing Xue
Outcome results
None listed